Gene editing and its application for hematological diseases

Research output: Contribution to journalReview article

16 Scopus citations

Abstract

The use of precise, rationally designed gene-editing nucleases allows for targeted genome and transcriptome modification, and at present, four major classes of nucleases are being employed: zinc finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), meganucleases (MNs), and clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9. Each reagent shares the ability to recognize and bind a target sequence of DNA. Depending on the properties of the reagent, the DNA can be cleaved on one or both strands, or epigenetic changes can be mediated. These novel properties can impact hematological disease by allowing for: (1) direct modification of hematopoietic stem/progenitor cells (HSPCs), (2) gene alteration of hematopoietic lineage committed terminal effectors, (3) genome engineering in non-hematopoietic cells with reprogramming to a hematopoietic phenotype, and (4) transcriptome modulation for gene regulation, modeling, and discovery.

Original languageEnglish (US)
Pages (from-to)18-28
Number of pages11
JournalInternational Journal of Hematology
Volume104
Issue number1
DOIs
StatePublished - Jul 1 2016

    Fingerprint

Keywords

  • Blood disorders
  • CRISPR/Cas9
  • Hematopoiesis
  • Hematopoietic stem cells
  • TALEN
  • ZFN

Cite this